$1.55
+0.13 (+9.15%)
Open$1.44
Previous Close$1.42
Day High$1.55
Day Low$1.40
52W High$2.23
52W Low$0.85
Volume—
Avg Volume454.0K
Market Cap37.58M
P/E Ratio—
EPS$-0.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,920.6% upside
Current
$1.55
$1.55
Target
$31.32
$31.32
$21.60
$31.32 avg
$37.71
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.32M | 9.26M | 9.19M |
| Net Income | 712.1K | 643.5K | 610.9K |
| Profit Margin | 7.6% | 7.0% | 6.7% |
| EBITDA | 971.8K | 983.2K | 961.2K |
| Free Cash Flow | 631.5K | 606.6K | 819.9K |
| Rev Growth | +16.1% | +5.9% | +8.5% |
| Debt/Equity | 1.16 | 1.10 | 1.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |